Been awhile, but Immuron is back on my radar. There’s a better vibe here now under the new manager and finally trials are moving forward. A ph2 c-diff trial is slated for next year. I never understood why they didn’t move forward with that years ago. Trial data is v positive and with growing sales I think raising funds for a phase3 and c-diff won’t be hard.
Everything feels nicely setup for an exciting few years ahead.
Good to see the old long suffering hardcore shareholders are still hanging in there.
IMC Price at posting:
9.7¢ Sentiment: Buy Disclosure: Not Held
